
Qiagen N.V.
QGEN
Updated: 23/09/2026, 12:34:43
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
No summaries found.
- Share price
- $43.69
- Market cap
- $9.01B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Jon Pratt
- Employees
- 5,500
- IPO date
- 28/06/1996
- Beta
- 0.626
- Last dividend
- $0.00
- Day range
- $43.63 – $44.47
- 52-week range
- $32.53 – $57.82
- 1-day performance
- -2.43%
- 1-year performance
- 34.31%
- Current drawdown (1Y)
- -24.44%
- CIK
- 0001015820
- CUSIP
- N/A
- ISIN
- NL0015002SN0
- Created
- 07/12/2025, 13:52:51
- Last update
- 23/09/2026, 12:34:43
Track Qiagen N.V. with an AI analyst
See which prediction-market events move QGEN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
Business Wire • STOCK • 15/06/2026, 03:30:00
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75
GuruFocus • STOCK • 09/06/2026, 21:52:00
Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 03/06/2026, 17:12:01
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
GlobeNewsWire • STOCK • 02/06/2026, 19:41:00
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
Zacks Investment Research • STOCK • 29/05/2026, 12:20:34
QIAGEN Business Breakdown and Growth Drivers for 2026
Zacks Investment Research • STOCK • 28/05/2026, 13:01:28
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
GlobeNewsWire • STOCK • 26/05/2026, 19:35:00
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
GlobeNewsWire • STOCK • 21/05/2026, 22:00:00
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
Zacks Investment Research • STOCK • 21/05/2026, 15:55:42
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
Business Wire • STOCK • 20/05/2026, 18:05:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
PRNewsWire • STOCK • 15/05/2026, 00:20:00
QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
GlobeNewsWire • STOCK • 14/05/2026, 21:00:00